Health Care • Biotechnology: Pharmaceutical Preparations
$59.95 ▼ -1.23
(-2.01%)
MKT CAP: $9.36B • VOL: 2.58M
52W L $27 52W H $62
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$50
MEDIAN
$67
MEAN
$68
HIGH
$82
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TGTX TAPE
TGTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $72.54 | $68.94 | 2025-02-14 | $54.55 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $75.54 | $70.74 | 2025-02-06 | $56.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $68.34 | $65.95 | 2025-01-29 | $57.55 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $61.15 | — | 2025-01-17 | $58.75 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $52.76 | $56.95 | 2025-01-09 | $53.36 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $71.34 | $62.35 | 2024-12-18 | $52.16 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $58.15 | $60.55 | 2024-12-04 | $55.75 | -4.3% | 48% | C |